Journal
JOURNAL OF ONCOLOGY
Volume 2021, Issue -, Pages -Publisher
HINDAWI LTD
DOI: 10.1155/2021/6649412
Keywords
-
Categories
Funding
- Beijing Jishuitan Hospital
- National Natural Science Foundation of China [51973021, 51932002]
- Beijing Natural Science Foundation [7192027]
- Beijing Municipal Health Commission [BMHC-2019-9, BMHC-2018-4, PXM2020_026275_000002]
- Beijing JST Research Funding [ZR-201902, YGQ-201925]
Ask authors/readers for more resources
The study identified five immune subtypes in osteosarcoma patients, each associated with distinct clinical outcomes. These immune subtypes also showed variations in tumor genetic aberrations, tumor-infiltrating immune cell composition, and cytokine profiles, revealing significant intracluster heterogeneity within each subtype and a continuous immune spectrum across patients.
Background. Osteosarcoma (OS) patients have a poor response to immunotherapy due to the sheer complexity of the immune system and the nuances of the tumor-immune microenvironment. Methodology. To gain insights into the immune heterogeneity of OS, we identified robust clusters of patients based on the immune gene expression profiles of OS patients in the TARGET database and assessed their reproducibility in an independent cohort collected from the GEO database. The association of comprehensive molecular characterization with reproducible immune subtypes was accessed with ANOVA. Furthermore, we visualized the distribution of individual patients in a tree structure by the graph structure learning-based dimensionality reduction algorithm. Results. We found that 87 OS samples can be divided into 5 immune subtypes, and each of them was associated with distinct clinical outcomes. The immune subtypes also demonstrated widely different patterns in tumor genetic aberrations, tumor-infiltrating, immune cell composition, and cytokine profiles. The immune landscape of OS uncovered the significant intracluster heterogeneity within each subtype and depicted a continuous immune spectrum across patients. Conclusion. The established five immune subtypes in our study suggested immune heterogeneity in OS patients and may provide optimal individual immunotherapy for patients exhibiting OS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available